Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Yunnan Baiyao Group Wenshan Qihua is a specialized subsidiary of the Yunnan Baiyao Group, primarily focused on the cultivation, processing, and distribution of Panax notoginseng (Sanqi). Located in Wenshan, Yunnan—the world's primary production area for this medicinal herb—the company leverages high-quality raw materials to produce traditional Chinese medicines and health products. Its portfolio includes the renowned Yunnan Baiyao series, which is used for wound healing, pain relief, and improving blood circulation. The company integrates modern pharmaceutical standards with traditional herbal expertise to maintain a leading position in the TCM market. It plays a critical role in the group's supply chain, ensuring the purity and efficacy of its core ingredients.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Yunnan Baiyao Group Wenshan Qihua.